October 21, 2020
CMIC Co., Ltd.
SUSMED, Inc.

 

Tokyo- October 21, 2020 -CMIC Co., Ltd. (henceforth “CMIC”) and SUSMED, Inc. (henceforth “SUSMED”)　have formed a strategic partnership to provide one-stop digital therapeutics (DTx) development services from app development to post-launch support. Through this partnership, the two companies will combine their expertise, resources, knowledge of clinical development and digital technologies market and channels to help advance the DTx market growth in Japan.

Starting today, October 21, 2020, CMIC and SUSMED will offer integrated contract services for the development of therapeutic apps and testing of such apps in clinical trials. These services will be available to pharmaceutical and IT companies in Japan and around the world. Concurrently, CMIC and SUSMED are also  developing additional services to enable a one-stop service platform that includes post-market patient and healthcare provider support, distribution and quality control systems, data security management, as well as funding support.

“CMIC began exploring the idea of offering CRO services for DTx in Japan around 2018. DTx will be an important field in the Japanese healthcare industry going forward, and it is a new market for which regulations and other infrastructure are just starting to be established. SUSMED shares the same pioneering spirit as CMIC to work outside the box. With this partnership we are now able to combine our knowledge in various areas to build and offer an integrated DTx service platform that covers all steps from development to post-launch support. It will support the continuous growth of the DTx market and help advance the healthcare industry in Japan.” said Toru Fujieda, President of CMIC Co., Ltd.

 

“DTx are a powerful tool for addressing unmet medical needs with existing therapies. At the same time, DTx have the potential to realize the vision of “sustainable medicine,” which aligns with the optimal goals of both individuals and society. Since its founding, SUSMED has developed digital technology aimed at realizing this vision. Leveraging this partnership with CMIC, we can provide our technology to a larger number of companies, and help accelerate the overall DTx market growth in Japan. We believe that building this one-stop service platform will allow us to deliver more treatment approaches to healthcare providers in Japan.” said Taro Ueno, CEO of SUSMED, Inc.

 ■About the partnership for development support services

Each of our companies is experienced in DTx development, and we will use this partnership to provide one-stop services such as development strategy consultations, system-building, and clinical trial operations. Our aim is to shorten development time and reduce risk by centralizing project tasks between companies. We will leverage CMIC Group’s resources such as our call center and capacity to conduct surveys of needs at medical institutions along with SUSMED’s patented technology for DTx development to build systems that allow us to cover DTx market needs at all stages, from development to post-launch support.

 To learn more about the DTx service platform, please contact us at dtx_prgroup@cmic.co.jp

 

■About CMIC group

CMIC Group was founded in 1992 as the first Contract Research Organization (CRO) in Japan. Today CMIC Group is the largest clinical CRO in Japan with global footprint, providing comprehensive services in drug development, clinical site management, clinical to commercial GMP manufacturing, regulatory consulting and contract sales & marketing solutions. We can help pharmaceutical, biotech and medical device companies to enter Japan market, to conduct clinical trials in Asia, or to bridge drug development and manufacturing needs in the US, Europe, Japan and broader Asia. CMIC Group has over 7,000 employees and 25 sites globally. For more information about CMIC Group and services, please visit our website.  https://en.cmicgroup.com/

 

■About SUSMED, Inc.

SUSMED Inc., is a research and development firm that is working to advance digital therapies. In addition to developing an app for treating insomnia, SUSMED provides a universal platform for developing medical apps, along with clinical trial support systems and automated AI analysis systems. SUSMED is advancing digital therapy grounded in technology, with patents in medical apps and blockchain applications in medical treatment. https://www.susmed.co.jp/en

 

【Contact us】

CMIC HOLDINGS Co., LTD. PR group

E-mail: pr@cmic.co.jp

 

SUSMED, Inc.

E-mail: support@susmed.co.jp